By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...